FY2025 EPS Estimates for Cytokinetics Cut by HC Wainwright

Cytokinetics, Incorporated (NASDAQ:CYTK) – Research analysts at HC Wainwright lowered their FY2025 earnings estimates for Cytokinetics in a report released on Monday, December 22nd. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of ($5.78) for the year, down from their previous estimate of ($5.75). HC Wainwright currently has a “Buy” rating and a $136.00 price target on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q4 2025 earnings at ($1.75) EPS.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.59) by $0.05. The company had revenue of $1.94 million for the quarter, compared to analyst estimates of $6.05 million. The business’s revenue for the quarter was up 318.1% on a year-over-year basis. During the same period last year, the company posted ($1.36) EPS.

A number of other research analysts have also recently weighed in on the company. Morgan Stanley lifted their target price on Cytokinetics from $65.00 to $71.00 and gave the company an “overweight” rating in a report on Monday. Bank of America lifted their price objective on Cytokinetics from $52.00 to $56.00 and gave the company a “neutral” rating in a research note on Thursday, October 2nd. UBS Group reiterated a “neutral” rating and set a $61.00 target price on shares of Cytokinetics in a report on Monday, December 1st. Leerink Partners set a $83.00 price target on shares of Cytokinetics in a report on Monday. Finally, The Goldman Sachs Group set a $95.00 price target on shares of Cytokinetics and gave the company a “buy” rating in a research report on Thursday, December 18th. Fifteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $83.61.

Cytokinetics Stock Down 3.5%

Shares of NASDAQ CYTK opened at $63.29 on Wednesday. The stock has a market capitalization of $7.74 billion, a PE ratio of -10.06 and a beta of 0.58. The firm has a fifty day moving average of $62.87 and a 200-day moving average of $49.10. Cytokinetics has a 52-week low of $29.31 and a 52-week high of $70.98.

Insider Activity

In other news, CEO Robert I. Blum sold 5,000 shares of Cytokinetics stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $55.05, for a total transaction of $275,250.00. Following the sale, the chief executive officer owned 368,108 shares in the company, valued at $20,264,345.40. This trade represents a 1.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Wendell Wierenga sold 20,000 shares of the business’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $66.14, for a total transaction of $1,322,800.00. Following the transaction, the director directly owned 32,444 shares in the company, valued at approximately $2,145,846.16. The trade was a 38.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 168,494 shares of company stock worth $10,811,018 in the last ninety days. 3.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cytokinetics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CYTK. Hudson Bay Capital Management LP boosted its position in Cytokinetics by 15.4% in the 3rd quarter. Hudson Bay Capital Management LP now owns 182,131 shares of the biopharmaceutical company’s stock valued at $10,010,000 after buying an additional 24,345 shares during the last quarter. Swiss Life Asset Management Ltd acquired a new position in shares of Cytokinetics in the third quarter worth about $283,000. CIBC Private Wealth Group LLC boosted its holdings in Cytokinetics by 8.1% in the third quarter. CIBC Private Wealth Group LLC now owns 3,484 shares of the biopharmaceutical company’s stock valued at $191,000 after purchasing an additional 261 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new position in Cytokinetics in the third quarter valued at about $684,000. Finally, Coldstream Capital Management Inc. acquired a new stake in Cytokinetics during the 3rd quarter valued at approximately $261,000.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: FDA approved Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy, turning Cytokinetics into a commercial-stage cardiology biotech and opening a new revenue runway — a primary driver behind the rally. Article Title
• Positive Sentiment: Multiple brokers lifted price targets and reiterated buy/outperform views (Barclays, Morgan Stanley, BofA, Needham, Citizens/JMP), signaling stronger analyst conviction on commercial prospects and supporting upside. Article Title
• Positive Sentiment: Unusually heavy call-option buying (about 5,619 calls, ~103% above typical daily volume) suggests traders are positioning for additional upside or near-term bullish moves. (Options volume report)
• Positive Sentiment: Analyst commentary highlights practical label advantages for MYQORZO vs. the incumbent (flexible dosing), and management targets substantial market share gains — commentary that supports a multi-quarter adoption story. Article Title
• Neutral Sentiment: Citizens maintained its Market Outperform rating on CYTK, which is supportive but not a new endorsement. Article Title
• Negative Sentiment: Insider selling: director Wendell Wierenga sold 20,000 shares at an average $66.14 (Dec. 22), trimming his stake ~38% — a potential short-term headwind or cautionary signal for some investors. SEC Filing

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.